Pharmacotherapy Information Center ( PIC )

وُلِـدَ الـهُـدى فَـالكائِناتُ ضِياءُ.. وَفَـمُ الـزَمـانِ تَـبَـسُّـمٌ وَثَناءُ الـروحُ وَالـمَـلَأُ الـمَلائِكُ حَولَهُ.. لِـلـديـنِ وَالـدُنـيـا بِهِ بُشَراءُ وَالـعَـرشُ يَزهو وَالحَظيرَةُ تَزدَهي.. وَالـمُـنـتَـهى وَالسِدرَةُ العَصماءُ وَحَـديـقَـةُ الفُرقانِ ضاحِكَةُ الرُبا.. بِـالـتُـرجُـمـ انِ شَـذِيَّةٌ غَنّاءُ وَالـوَحيُ يَقطُرُ سَلسَلًا مِن سَلسَلٍ.. وَالـلَـوحُ وَالـقَـلَـمُ البَديعُ رُواءُ نُـظِمَت أَسامي الرُسلِ فَهيَ صَحيفَةٌ.. فـي الـلَـوحِ وَاِسمُ مُحَمَّدٍ طُغَراءُ اِسـمُ الـجَـلالَةِ في بَديعِ حُروفِهِ.. أَلِـفٌ هُـنـالِـكَ وَاِسمُ طَهَ الباءُ #اللهم صل وسلم وبارك وتحنن وترحم على سيدنا محمد وعلى آله وصحبه أجمعين

ضاءت بك الدنيا وعشت ممجدًا.. وغبت عن الدنيا وما زلت سيِّدًا .. عليك سلام الله في كل خفقة.. فقد ماتت الأسماء إلا محمدًا في ذكرى المولد النبوي الشريف على صاحبه أفضل الصلاة والسلام ، أكثرو من الصلاة والسلام على اشرف الانبياء والمرسلين

كل القلوب إلى الحبيب تميل .. ومعي بهذا شاهد ودليل أما الدليل إذا ذكرت محمدًا.. صارت دموع العارفين تسيل ..هذا نبراس الهدى.. هذا لكل العالمين رسول.

Management Algorithm for Nonalcoholic Fatty Liver Disease Overview 📌American Association of Clinical Endocrinology (AACE) https://t.me/PIC_uptodate77

📋Cholesterol Management Guide for Health Care Practitioner 📌American Heart Association (AHA) https://t.me/PIC_uptodate77

DEFENCATH دواء جديد تم إضافته مع الهيبارين  ليكون صنف دوائي جديد يحتوي على combination من الHeparin and taurolidine حيث أن الtaurolidine دواء  مضاد للميكروبات Antimicrobial drug هذا المركب الدوائي تحت اسم DEFENCATH Initial U.S. Approval: 2023 هذا المركب الدوائي(DEFENCATH ) يستخدم لتقليل حدوث العدوى المصاحبة للقسطرة (CRBSI) عند مرضى الفشل الكلوي البالغين الذين يخضعون لغسيل كلوي مزمن بواسطة Central Venous Catheter (CVC) 💊DEFENCATH (taurolidine and heparin) catheter lock solution, for central venous catheter instillation use 1⃣INDICATIONS AND USAGE DEFENCATH is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients. 2⃣Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. 3⃣-DOSAGE AND ADMINISTRATION DEFENCATH is for instillation into CVCs only. DEFENCATH is not intended for systemic administration. Do not use DEFENCATH as a catheter lock flush product. Withdraw a sufficient volume of DEFENCATH catheter lock solution (CLS) from the vial using a sterile needle and syringe to fill the catheter lumens. Use 3 mL or 5 ml. single dose vial (depending on the volume of the catheter lumens) to instill DEFENCATH into each catheter lumen at the conclusion of each HD session. DEFENCATH must be aspirated from the catheter and discarded prior to the initiation of the next HD session. Discard any unused portion of DEFENCATH remaining in the vial. 4⃣DOSAGE FORMS AND STRENGTHS-- DEFENCATH is a sterile catheter lock solution available in single- dose vials in the following strengths: 3 mL containing taurolidine 40.5 mg/3 mL (13.5 mg/mL), and heparin 3,000 USP Units/3 mL (1,000 USP Units/mL) 5 mL containing taurolidine 67.5 mg/5 mL (13.5 mg/mL), and heparin 5,000 USP Units/5 mL (1,000 USP Units/mL) 5⃣---CONTRAINDICATIONS- Known heparin-induced thrombocytopenia. Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products. 6⃣---WARNINGS AND PRECAUTIONS--- Heparin-Induced Thrombocytopenia (HIT): HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures. Drug Hypersensitivity Reactions: Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% in patients using heparin, a component of DEFENCATH, as a CLS. If a hypersensitivity reaction occurs, discontinue DEFENCATH and institute appropriate supportive measures. 7⃣ADVERSE REACTIONS-- The most frequently reported adverse reactions occurring in greater than or equal to 2% of patients in Trial 1 using DEFENCATH as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia. https://t.me/PIC_uptodate77

2024 ACC HFrEF experts Guideline 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction American College of Cardiology https://t.me/PIC_uptodate77